Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides

Oligodeoxynucleotide libraries containing randomly incorporated bases are used to generate DNA aptamers by systematic evolution of ligands by exponential enrichment (SELEX). We predicted that combinatorial libraries with alternative base compositions might have innate properties different from the standard library containing equimolar A + C + G + T bases. In particular, we hypothesized that G-rich libraries would contain a higher proportion of quadruplex-forming sequences, which may impart desirable qualities, such as increased nuclease resistance and enhanced cellular uptake. Here, we report on 11 synthetic oligodeoxynucleotide libraries of various base combinations and lengths, with regard to their circular dichroism, stability in serum-containing medium, cellular uptake, protein binding and antiproliferative activity. Unexpectedly, we found that some G-rich libraries (composed of G + T or G + C nucleotides) strongly inhibited cancer cell growth while sparing non-malignant cells. These libraries had spectral features consistent with G-quadruplex formation, were significantly more stable in serum than inactive libraries and showed enhanced cellular uptake. Active libraries generally had strong protein binding, while the pattern of protein binding suggested that G/T and G/C libraries have distinct mechanisms of action. In conclusion, cancer-selective antiproliferative activity may be a general feature of certain G-rich oligodeoxynucleotides and is associated with quadruplex formation, nuclease resistance, efficient cellular uptake and protein binding.

[1]  M. Famulok,et al.  RNA aptamers specifically interact with the prion protein PrP , 1997, Journal of virology.

[2]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[3]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[4]  E. Kandel,et al.  RNA-mediated response to heat shock in mammalian cells , 2006, Nature.

[5]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[6]  G. Mayer.  The chemical biology of aptamers. , 2009, Angewandte Chemie.

[7]  P. Bates,et al.  Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. , 2002, Biochemistry.

[8]  B. Sullenger,et al.  Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies , 1997, Nature Biotechnology.

[9]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[10]  Mark W. Ball,et al.  AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. , 2006, Molecular cancer therapeutics.

[11]  Weihong Tan,et al.  Applications of aptamers in cancer cell biology. , 2008, Analytica chimica acta.

[12]  M Guéron,et al.  The i-motif in nucleic acids. , 2000, Current opinion in structural biology.

[13]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[14]  P. Bates,et al.  Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. , 2003, Nucleic acids research.

[15]  G. Dreyfuss,et al.  Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n , 1993, Molecular and cellular biology.

[16]  L. Kèlland,et al.  Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.

[17]  N. Maizels,et al.  G4 DNA Binding by LR1 and Its Subunits, Nucleolin and hnRNP D, A Role for G-G pairing in Immunoglobulin Switch Recombination* , 1999, The Journal of Biological Chemistry.

[18]  Anthony D. Keefe,et al.  SELEX with modified nucleotides. , 2008, Current opinion in chemical biology.

[19]  Paula J. Bates,et al.  AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin , 2006, Molecular Cancer Therapeutics.

[20]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[21]  T. Kohwi-Shigematsu,et al.  Nucleolin is a matrix attachment region DNA-binding protein that specifically recognizes a region with high base-unpairing potential , 1995, Molecular and cellular biology.

[22]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[23]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[24]  T. Kipps,et al.  Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. , 2003, Human gene therapy.

[25]  Jaroslav Kypr,et al.  Circular dichroism and conformational polymorphism of DNA , 2009, Nucleic acids research.

[26]  F. Ducongé,et al.  Aptamers against extracellular targets for in vivo applications. , 2005, Biochimie.

[27]  L. Hurley,et al.  Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene , 2008, Nucleic acids research.

[28]  B. Sullenger,et al.  Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. , 2007, Oligonucleotides.

[29]  N. Maizels,et al.  High Affinity Interactions of Nucleolin with G-G-paired rDNA* , 1999, The Journal of Biological Chemistry.